药物活性成分优选格列齐特。
目的：对格列齐特缓释片进行质量标准研究。
Objective: To study the quality specification of Gliclazide Sustained-release Tablet.
用药金额排名前3位的药物是阿卡波糖、格列齐特、格列吡嗪。
The top 3 hypoglycemic drugs in respect of sales amount were acarbose, gliclazide, and glipizide.
目的研究格列齐特片的健康人体药物动力学及相对生物利用度。
Objective To study the relative bioavailability of gliclazide in healthy volunteers.
结论乳糖和格列齐特一定比例下经高速研磨混合的样品形成了共熔体；
Conclusion The sample of Galactosylglucose and Gliclazide can form solid dispersion by high speed grinding.
目的：观察吡格列酮联用格列齐特缓释片治疗2型糖尿病的临床疗效。
Objective: To study the clinical effects of pioglitazone combined with glipizide on type 2 diabetes therapy.
这种影响作用可通过将细胞培养在含抗vegf抗体中而消除，格列齐特也可抑制这种作用。
This effect was abrogated by incubating the cells with an anti-VEGF antibody and was inhibited in the presence of gliclazide.
结论格列齐特控释片治疗2型糖尿病的临床疗效和对生存质量的影响与格列齐特普通片相似。
Conclusion Controlled-release-gliclazide had the similar effect on the patients with type 2 diabetes as ordinary gliclazide tablets did in improving their clinical manifestation and quality of life.
研究背景：现状研究的目的是比较服用格列苯脲和格列齐特患者之间全造成的心血管与非心血管病死亡率、心血管病发病率。
BACKGROUND: Aim of the present study is the comparison of all-cause, cardioascular and non-cardioascular mortality, and cardiac morbidity, between patients treated with glibenclamide and gliclazide.
方法将符合IR及脂代谢紊乱诊断的2型糖尿病患者56例随机分别予口服二甲双胍（A组）、格列齐特（B组）治疗3个月。
Methods 56 patients with IR and fat metabolism disorder were randomly given oral dimethyldiguanide (group A) and Gliclazide capsule (group B) for 3 months.
方法将符合IR及脂代谢紊乱诊断的2型糖尿病患者56例随机分别予口服二甲双胍（A组）、格列齐特（B组）治疗3个月。
Methods 56 patients with IR and fat metabolism disorder were randomly given oral dimethyldiguanide (group A) and Gliclazide capsule (group B) for 3 months.
应用推荐